PureTech Health PLC (PRTC)
| Market Cap | 1.53B |
| Revenue (ttm) | 11.77M |
| Net Income (ttm) | 4.57M |
| Shares Out | 285.74M |
| EPS (ttm) | 0.20 |
| PE Ratio | 284.00 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $56.80 |
| Previous Close | $56.80 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 54.20 - 59.00 |
| Day's Volume | 18 |
| 52-Week Range | 33.00 - 65.90 |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using rationally defined bacterial consortia manufactured ...
BOSTON--(BUSINESS WIRE)--PureTech Announces Nature Publication Supporting Modulation of Meningeal Lymphatics to Target Alzheimer's Disease Pathologies
PureTech Founded Entity Gelesis Appoints Procter & Gamble Veteran Jane Wildman to Board of Directors
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Gelesis Appoints Procter & Gamble Veteran Jane Wildman to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using rationally defined bacterial consortia manufactured ...
BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2020
BOSTON--(BUSINESS WIRE)--PureTech Presents Promising Preclinical Data from LYT-210 Immuno-Oncology Program at American Association for Cancer Research (AACR) Annual Meeting
BOSTON--(BUSINESS WIRE)--PureTech to Present at Two Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing hi...
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Announces the Results of EndeavorRx™ Clinical Study in Pediatric ADHD Published in Nature Digital Medicine
BOSTON--(BUSINESS WIRE)--PureTech announces Stephen Muniz, Esq., will retire from his role as Chief Operating Officer and will step down from the Board Of Directors.
BOSTON--(BUSINESS WIRE)--Notice of Results
BOSTON--(BUSINESS WIRE)--PureTech to Present at The Barclays Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using rationally defined bacterial consortia manufactured ...
BOSTON--(BUSINESS WIRE)--PureTech Announces Publication of Glyph Platform Preclinical Proof-of-Concept Study in Journal of Controlled Release
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing hi...
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vor Biopharma Closes Over $200M Initial Public Offering
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta announces $25 million investment from Pfizer Inc. as part of the Pfizer Breakthrough Growth Initiative.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta announces $25 million investment from Pfizer Inc. as part of the Pfizer Breakthrough Growth Initiative.
BOSTON--(BUSINESS WIRE)--PureTech (Nasdaq: PRTC) initiated a global, Phase 2 trial of LYT-100 (deupirfenidone) in Long COVID respiratory complications and related sequelae.
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors
About PRTC
PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic ... [Read more...]
| Industry Biotechnology | |
| CEO Daphne Zohar | Employees 250 |
| Stock Exchange NASDAQ | Ticker Symbol PRTC |
Financial Performance
In 2020, PRTC's revenue was $11.77 million, an increase of 20.00% compared to the previous year's $9.81 million. Earnings were $4.57 million, a decrease of -98.75%.
Analyst Forecasts
The average 12-month stock price forecast for PRTC is 73.50, which is an increase of 29.40% from the latest price.